← Research library

Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial

Randomized study in people · 2012

What was studied
CASTA: 1,070 acute ischemic-stroke patients; randomized within 12 hours; 90-day follow-up
Main finding
The combined primary outcome showed no significant benefit. A favorable signal in more severe strokes arose in post-hoc analysis.

Reported findings and study design

CASTA: 1,070 patients, randomized within 12 hours; Cerebrolysin 529 versus placebo 541. Intravenous 30 mL/day for ten days plus aspirin 100 mg/day; 90-day follow-up.

Population or model CASTA: 1,070 acute ischemic-stroke patients; randomized within 12 hours; 90-day follow-up

Dose, route and schedule

Cerebrolysin: 30 mL intravenously daily for 10 days, starting within 12 hours of stroke onset. Background treatment included aspirin 100 mg/day; the comparison used placebo.

Protocol source ↗ · Indexed publication abstract

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
MeasureResultComparison, timing and statistics
Combined primary outcomeNo significant between-group difference
Severe-stroke subgroup: NIHSS outcomeOR 1.27; lower CI bound 0.97Exploratory subgroup with baseline NIHSS>12
Severe-stroke subgroup: mRS outcomeOR 1.27; lower CI bound 0.90Exploratory subgroup
Severe-stroke subgroup: 90-day mortality10.5% Cerebrolysin versus 20.2% placeboAbstract reports HR 1.9661 and lower CI bound 1.0013; direction follows the source

Primary result was neutral. Subgroup findings are post hoc; the incomplete confidence intervals are reproduced without inventing upper bounds.

Source for these results ↗ · Reviewed 2026-10-29

Study limitations and source details

Study limitations

  • The severe-stroke subgroup is exploratory, not confirmation of efficacy.
  • The meta-analyses that include CASTA already account for this trial.

Source details

Indexed citation and abstract reviewed via Europe PMC / PubMed; full methods and risk of bias not comprehensively appraised.

Abstract reviewed

Sources checked

Citation

Randomized trialEnglish abstract

Heiss WD, Brainin M, Bornstein NM, Tuomilehto J, Hong Z, Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial Stroke · PMID 22282884

Study source ↗ · DOI 10.1161/strokeaha.111.628537 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards